Globus Medical FY2025 EPS Estimate Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research boosted their FY2025 earnings estimates for shares of Globus Medical in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $3.43 for the year, up from their prior forecast of $3.42. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $0.97 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company’s revenue was up 63.1% on a year-over-year basis. During the same quarter last year, the business posted $0.57 earnings per share.

GMED has been the subject of a number of other reports. Stifel Nicolaus lifted their price target on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. StockNews.com lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Truist Financial increased their price target on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group upped their price objective on Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a research note on Thursday, January 9th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.91.

Globus Medical Price Performance

GMED stock opened at $92.42 on Thursday. The stock has a market capitalization of $12.59 billion, a price-to-earnings ratio of 137.94, a P/E/G ratio of 1.76 and a beta of 1.19. The business has a fifty day moving average price of $84.64 and a 200 day moving average price of $76.45. Globus Medical has a fifty-two week low of $49.33 and a fifty-two week high of $93.67.

Institutional Investors Weigh In On Globus Medical

Several hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in shares of Globus Medical by 2.3% in the 3rd quarter. State Street Corp now owns 3,570,726 shares of the medical device company’s stock valued at $255,450,000 after buying an additional 81,371 shares in the last quarter. Geode Capital Management LLC grew its stake in Globus Medical by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,885,061 shares of the medical device company’s stock valued at $134,893,000 after acquiring an additional 21,935 shares during the period. Geneva Capital Management LLC increased its holdings in shares of Globus Medical by 1.1% in the third quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company’s stock worth $114,330,000 after acquiring an additional 18,117 shares in the last quarter. AXA S.A. increased its holdings in shares of Globus Medical by 0.5% in the second quarter. AXA S.A. now owns 1,478,242 shares of the medical device company’s stock worth $101,245,000 after acquiring an additional 7,443 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Globus Medical by 1,171.5% during the second quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock worth $93,409,000 after purchasing an additional 1,256,570 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Kelly Huller sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Insiders sold a total of 81,667 shares of company stock valued at $6,674,554 over the last three months. Company insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.